TMCnet News
Dr Reddy's starts diabetes drug's final test(Ecomonic Times, The (India) (KRT) Via Thomson Dialog NewsEdge) Aug. 2--HYDERABAD, India -- The stage has been set for the creation of the country's first intellectual property in the pharma segment with Dr Reddy's and Rheoscience beginning the phase III clinical trials of anti-diabetic drug balagliatzone (DRF-2593). The drug, meant to treat type 2 diabetes, has been jointly developed by Dr Reddy's and its partner Danish pharma major Rheoscience. If the drug passes the final stage of testing, India will find a place in the international arena as a drug discovering nation. The country has a track-record of successfully creating product patents in the past. The anti-diabetic drug (DRF 2593) will be the first original product patent in the pharmaceutical segment from the country, after the introduction of the product patent regime in 2005. The trials mark the first global phase III clinical trials of a Dr Reddy's new chemical entity. Rheoscience will retain the drug's marketing rights for the EU and China while Dr Reddy's will possess marketing rights for the US and the rest of the world. According to the pact between the two, Rheoscience will get regulatory approvals for the drug on behalf of DRL in the US. To see more of The Economic Times, or to subscribe to the newspaper, go to http://economictimes.indiatimes.com Copyright (c) 2007, The Economic Times, India Distributed by McClatchy-Tribune Information Services. For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA. |